Compare AVO & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVO | PHAT |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 894.0M |
| IPO Year | 2020 | 2019 |
| Metric | AVO | PHAT |
|---|---|---|
| Price | $12.06 | $11.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $17.00 | ★ $19.83 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 06-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.92 | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,391,200,000.00 | $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | $3.06 | $58.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.68 | ★ 216.93 |
| 52 Week Low | $10.00 | $3.69 |
| 52 Week High | $15.53 | $18.31 |
| Indicator | AVO | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 31.09 | 48.15 |
| Support Level | $11.55 | $10.38 |
| Resistance Level | $12.21 | $12.52 |
| Average True Range (ATR) | 0.47 | 0.98 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 0.19 | 61.97 |
Mission Produce Inc produces, packs, and distributes mainly Hass avocados to retail, wholesale, and food service customers, offering pre-ripe and ripened fruit tailored to customer specifications through its network of ripening facilities. The Company operates through three segments: Marketing & Distribution, which sources and distributes fruit globally and generates the majority of revenue; International Farming, which owns and operates avocado orchards and supplies fruit mainly to Marketing & Distribution, with operations principally in Peru and Guatemala; and Blueberries, which farms blueberries sold under an exclusive marketing agreement. The Company's operations span Peru, the United States, Guatemala, Mexico, Europe, and Canada.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.